Search

Tamoxifen

[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.

Exemestane

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal … It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Zopiclone

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. … In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

Travoprost

It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension. … [L49434] Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced

Gliclazide

[A39546] On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.

Cinacalcet

Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe.

Pseudoephedrine

Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system. … [A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889.

Prednisone

[A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]

Ezetimibe

intestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption. … [A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings

Human Recombinant Bone Morphogenetic Protein 4